Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Find out the essential features that determine the best cash back cards without fees, helping you make informed choices.
24,070 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
A top China logistics platform generated $1.8 billion in revenue last year, yet one investor cashed out a $6 million ...
The world runs on chips, and ON Semiconductor sits at an important crossroads of EVs, automation, and data centers. T...
SpaceX is hinting at a bold new business path beyond rockets and Starlink. This article breaks down what spacex's sta...
Palantir stock has faced volatility, but March is showing momentum. This deep dive explores why March could turning p...
A 67-year-old retiree pursues $1,950 monthly from a $325,000 pool, using a disciplined four-fund approach to target a...
Memory demand is reshaping the sector, and Micron sits at the center. This guide explains what drives micron technolo...
Oklo stock popped today after a regulatory milestone signaled progress for the company’s Aurora fast-fission technolo...
CoreWeave faces a split verdict as revenue surges and debt refinancing looms. The market must decide whether it becom...
An upbeat analyst stance helped lift shares of the first watch restaurant group. This article breaks down the catalys...
In a landscape defined by budget cycles and rapid tech shifts, L3Harris Technologies stands out with a 7.1 rating in ...
A game-changing cloud contract could reshape SpaceX’s IPO narrative. This article breaks down what google's $920 mill...